Bizotic Lifescience Profile
Key Indicators
- Authorised Capital ₹ 4.50 Cr
- Paid Up Capital ₹ 4.50 Cr
- Company Age 9 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.90 Cr
- Revenue Growth 293.57%
- Profit Growth -96.76%
- Ebitda -17.34%
- Net Worth 0.84%
- Total Assets 30.49%
About Bizotic Lifescience
Bizotic Lifescience Private Limited (BLPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 April 2015 (Nine years and ten months 11 days old ). Its registered office is in Jamnagar, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.50 Cr and a paid-up capital of Rs 4.50 Cr.
The company currently has active open charges totaling ₹5.90 Cr.
Jaydeep Shersiya, Rajesh Barasara, Rajnish Barasara, and One other member serve as directors at the Company.
Company Details
- Location
Jamnagar, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33111GJ2015PTC082917
- Company No.
082917
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Apr 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Bizotic Lifescience?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jaydeep Shersiya  | Director | 17-Apr-2015 | Current |
| Rajesh Barasara | Director | 17-Apr-2015 | Current |
| Rajnish Barasara | Director | 17-Apr-2015 | Current |
| Bharatbhai Rupala | Director | 17-Apr-2015 | Current |
Financial Performance of Bizotic Lifescience.
Bizotic Lifescience Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 293.57% increase. The company also saw a substantial fall in profitability, with a 96.76% decrease in profit. The company's net worth moved up by a moderate rise of 0.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bizotic Lifescience?
In 2022, Bizotic Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.90 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 5.90 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Aug 2016 | Others | ₹5.90 Cr | Open |
How Many Employees Work at Bizotic Lifescience?
Unlock and access historical data on people associated with Bizotic Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bizotic Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bizotic Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.